Article
AstraZeneca's rare disease arm in $1 bln deal for Pfizer gene therapies
Rating:
0.0
Views:
63
Likes:
1
Library:
1
AstraZeneca said on Friday its Alexion unit had agreed to buy U.S. drugmaker Pfizer's early-stage rare disease gene therapy portfolio for up to $1 billion, plus royalties on sales, as the British drugmaker bets on new genetic therapies.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value